NVONovo Nordisk A/S

$47.19

$34.7652 weeks$61.72

Price

$47.19+1.5%1Y

1M-2.1%1Y+1.5%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Top tier

9/10

Value71

Quality87

Momentum39

Growth72

Strongest Quality, weakest Momentum · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

Novo Nordisk is a global healthcare company and a world leader in Obesity and Diabetes care. The Company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. Headquartered in Denmark, Novo Nordisk employs more than 69,500 employees in around 80 countries, and markets its products in approximately 170 countries. The Company has a broad product portfolio across Obesity and Diabetes care and Rare disease, including a portfolio of glucagon-like-peptide-1 (GLP-1) receptor agonists for the treatment of obesity and diabetes, and modern and human insulins for the treatment of diabetes.

In the company’s own words · 20-F filed Feb 4, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$191.24B

1Y Return+1.5%

5Y Return+13%

For the full year FY2025, revenue was DKK 309.1B (+6.4% year on year) and net income DKK 102.4B.